In a nutshell The current study examined the safety and effectiveness of the chemotherapy combination ABVD in early-stage Hodgkin lymphoma patients over the age of 60. This study concluded that the standard four cycles of ABVD led to increased need for dose reduction and increased negative effects in older patients. Some background While the...
Read More
In a nutshell This study examined whether the number of chemotherapy agents in the combination ABVD could be reduced when treating Hodgkin lymphoma. The authors concluded that to be effective all four chemotherapies need to be included. Some background More than 80% of patients with early-stage, favorable Hodgkin lymphoma experience long-term...
Read More
In a nutshell This trial compared the safety and effectiveness of treatment with ABVD chemotherapy with or without radiation and radiation alone in patients with early-stage (stage I or II) Hodgkin lymphoma. The authors concluded that ABVD alone was associated with a higher overall survival (time from treatment until death due to any cause) rate. This...
Read More
In a nutshell This study examined the safety and effectiveness of the Stanford V chemotherapy combination in patients with early-stage Hodgkin lymphoma. The authors concluded that Stanford V was effective in the long-term in these patients. Some background Early-stage Hodgkin lymphoma (stages I-II) is considered to be a curable disease. Treatment...
Read More
